In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor.
Chi
Liguo
L
Cardiovascular Pharmacology, Pfizer Global R&D, Ann Arbor Laboratories, Ann Arbor, Michigan 48105, USA. Liguo.Chi@pfizer.com
Peng
Yun-Wen
YW
Gibson
Glenn
G
Hicks
Gary
G
Mertz
Thomas E
TE
Rapundalo
Stephen
S
Janiczek
Nancy
N
Edmunds
Jeremy J
JJ
Leadley
Robert
R
D000818:Animals; D001760:Bleeding Time; D002712:Chlorides; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D065427:Factor Xa Inhibitors; D005290:Ferric Compounds; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D007275:Injections, Intravenous; D010314:Partial Thromboplastin Time; D011517:Prothrombin Time; D011810:Quinoxalines / Q000008:administration & dosage / Q000494:pharmacology*; D011817:Rabbits; D013045:Species Specificity; D013927:Thrombosis / Q000139:chemically induced / Q000188:drug therapy; D013997:Time Factors
D002712:Chlorides; D065427:Factor Xa Inhibitors; D005290:Ferric Compounds; D005343:Fibrinolytic Agents; C501117:PD-198961; D011810:Quinoxalines; C024555:ferric chloride